TIME
Best Inventions for Medical Care
2024

Skin Cancer Detection, **Simplified.**

An objective, non-invasive skin cancer evaluation platform, accessible at the point of care.

FDA Cleared. Available in the United States.

DermaSensor™ Features

- Handheld, point-and-click application
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- AI-powered, ultra-miniaturized ESS technology

Major Findings from Clinical Studies

- ✓ 96% device sensitivity for detecting all skin cancers[1]
- ✓ PCPs' overall skin cancer sensitivity was found to increase by 6-9%; false negative referrals (i.e. missed skin cancers) decreased by 30-52% [2,3]
- ✓ PCPs' melanoma sensitivity was found to increase by 7-9%; false negative referrals (i.e. missed skin cancers) decreased by 21-30%[2]*
- ✓ Overall device accuracy (i.e. AUROC) was 79%; physician accuracy was 74% for all lesions and 56% for lesions in which they had low confidence in their clinical assessment*
- ✓ Device correctly classified 21-33% of benign lesions that physicians biopsied [1,4]
- ✓ Malignancy likelihood for the 1-10 score ranged from 6% to 61%; higher device scores can be used to objectively, systematically prioritize referrals of high-risk patients. [1,3]

Major FDA Cleared Product Firsts

- ✓ First skin cancer device developed for PCPs
- ✓ First FDA Breakthrough device for skin cancer
- ✓ First automated device indicated for all three common skin cancers (Melanoma, BCC and SCC)
- ✓ Only skin cancer device available that provides any risk assessment using any type of imaging or optical technology

Only FDA Cleared AI Skin Cancer Device For Physicians

Rapid and Reliable Recordings

Take five recordings in seconds, each of which takes a non-invasive sample of lesion tissue of approximately 0.7 mm (length) × 0.4 mm (width) × 0.5 mm (depth)

Easy To Learn and Use

No training seminars or courses needed, just minutes of reading the device Instructions for Use

FDA Breakthrough, Non-Invasive Technology

Show patients that their skin health is your priority by using FDA Cleared, objective, AI-powered technology

No Up-Front Capital Expense

An affordable way to add an additional service for patients, without a large up-front expense

Know More. Detect Now.

Set your practice apart by offering non-invasive, point-of-care skin cancer testing. DermaSensor empowers physicians by providing objective, actionable results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically.

DermaSensor Patient Education Resource Center
A user-friendly portal that enables customizable patient education materials tailored to your practice.

Hassle-Free Returns
Hassle-free returns after 90 days, month-to-month billing & no restocking fees.

Accessories Included
Charging dock, power supply, and regional power adapter blades.

On-Demand, Customer Support
If you have any questions regarding DermaSensor, our support team is here to help.

Cloud Storage Access
Customers can access all of their device usage logs and results.



One-Click Updates
Software updates directly to your DermaSensor.

Physician Finder
Helps elevate your practice: Unlock new patient opportunities by joiningthe physician finder.

E-Learning Courses
Free access to courses for you and your employees.

Remote Device Monitoring
Device functionality can be assessed remotely by our support team.

The only skin cancer detection device designed specifically for PCPs.

Assessing DermaSensor's Real-World Impact
To learn more, scan the QR code to download the latest white paper.

For more information go to:
www.dermasensor.com
or Contact Us
(855)-373-6767

DermaSensor

References

1. Merry SP, Chatha K, Croghan I, Nguyen VL, McCormick B, Leffel D. Clinical Performance of Novel Elastic Scattering Spectroscopy (ESS) in Detection of Skin Cancer: A Blinded, Prospective, Multi-Center Clinical Trial. J Clin Aesthet Dermatol 2023 April: 16(4 Suppl): s16. **2.** Data on file **3.** Seiverling EV, Agresta T, Cyr P, Caines L, Nguyen VL, Chatha K, Siegel DM. Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physician's Detection of Skin Cancers. J Clin Aesthet Dermatol 2023 April: 16(4 Suppl): s16-17. **4.** Hartman RI, Trepanowski N, Chang MS, Tepedino K, Gianacas C, McNiff JM, Fung M, Braghiroli NF, Grant-Kels JM, Multicenter Prospective Blinded Melanoma Detection Study with a Handheld Elastic Scattering Spectroscopy Device, JAAD International (2023), doi: https://doi.org/10.1016/j.jdin.2023.10.011. **5.** J. Boyer, J. R. Mourant, and I. J. Bigio, "Theoretical and Experimental Investigations of Elastic Scattering Spectroscopy as a Potential Diagnostic for Tissue Pathologies," in Advances in Optical Imaging and Photon Migration, (Optica Publishing Group, 1994), paper OPTTM.265.

*Melanoma false negative results are only reported from the two studies powered for analysis by individual skin cancer types, DERMSUCCESS pigmented reader study and DERM-ASSESS III reader study

About

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip clinicians for skin cancer detection. The DermaSensor device is an affordable, handheld tool that uses spectroscopy and algorithms to immediately evaluate skin lesions for cancer. DermaSensor is currently FDA Cleared, CE Marked, and is available for sale in the U.S.

AAFP PARTNER